Moderna (MRNA) Operating Income: 2017-2025
Historic Operating Income for Moderna (MRNA) over the last 8 years, with Sep 2025 value amounting to -$260.0 million.
- Moderna's Operating Income fell 271.43% to -$260.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.5 billion, marking a year-over-year decrease of 28.59%. This contributed to the annual value of -$3.9 billion for FY2024, which is 6.94% up from last year.
- According to the latest figures from Q3 2025, Moderna's Operating Income is -$260.0 million, which was up 71.33% from -$907.0 million recorded in Q2 2025.
- Moderna's Operating Income's 5-year high stood at $5.4 billion during Q4 2021, with a 5-year trough of -$2.0 billion in Q3 2023.
- In the last 3 years, Moderna's Operating Income had a median value of -$1.1 billion in 2025 and averaged -$945.5 million.
- Its Operating Income has fluctuated over the past 5 years, first skyrocketed by 2,609.84% in 2021, then plummeted by 20,866.67% in 2024.
- Quarterly analysis of 5 years shows Moderna's Operating Income stood at $5.4 billion in 2021, then slumped by 70.79% to $1.6 billion in 2022, then crashed by 99.62% to $6.0 million in 2023, then tumbled by 20,866.67% to -$1.2 billion in 2024, then tumbled by 271.43% to -$260.0 million in 2025.
- Its last three reported values are -$260.0 million in Q3 2025, -$907.0 million for Q2 2025, and -$1.1 billion during Q1 2025.